O
Oviva Therapeutics
Biotech & Life Sciences · New York City, United States · Founded 2021
A movement to improve women's experience of aging through biomedical research, development and advocacy MoreLess
Oviva Therapeutics is a pioneering startup that is developing first-of-its-kind therapeutics to enhance ovarian function and extend the healthspan of women. The company operates in the healthcare and biotechnology market, specifically focusing on women's health. The business model of Oviva Therapeutics revolves around the research, development, and commercialization of novel therapeutics that target ovarian function and longevity.
The company's primary clients are women who are experiencing or are at risk of age-related decline in ovarian function, which can lead to adverse health outcomes. Oviva Therapeutics aims to address this issue by developing innovative treatments that can extend the healthspan of women, thereby improving their overall health, well-being, and longevity.
The company generates revenue through the development and sale of these therapeutics. As the company's therapeutics are first-in-class, they have the potential to capture a significant market share in the women's health sector, providing a substantial revenue stream for the company.
Oviva Therapeutics is led by Daisy Robinton, PhD, who serves as the CEO and Co-Founder. The company is committed to not only developing effective therapeutics but also to elevating the broader conversation around women's health and building a coalition to drive this vision forward.
Keywords: Women's Health, Ovarian Function, Healthspan Extension, Therapeutics, Biotechnology, Healthcare, Age-Related Decline, Novel Treatments, Longevity, Oviva Therapeutics.
Company overview
Oviva Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 55.0
Valuation & funding
Oviva Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2025 | $0 | — | Granata Bio | ↗ |
| SEED✓Equity / VC | May 2022 | $12M | $46M | Cambrian BioPharma | ↗ |
| SPINOUT✓Other financing | Jan 2021 | $0 | — | Harvard Medical School · Massachusetts General Hospital | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $100K | 0% | 1 |
| 2025 | $100K | 0% | 1 |
| 2024 | $100K | 0% | 3 |
| 2023 | $100K | 0% | 5 |
| 2022 | $100K | — | 2 |
Growth signals
Oviva Therapeutics website traffic
Latest recorded traffic for Oviva Therapeutics is 3.2K monthly website visits, up 100% over the last three months. Oviva Therapeutics's team grew 0% over the past year.
Comparisons
Oviva Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Oviva Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Oviva Therapeutics's cap table
Sourced from Dealroom's funding and investor records.




Global footprint
Where Oviva Therapeutics has talent and traffic
team presence
In the news
Latest news about Oviva Therapeutics
Recent press, funding announcements, and product moves mentioning Oviva Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Oviva Therapeutics
An AI-synthesized read of the highest-engagement posts about Oviva Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oviva Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







